ADVERTISEMENT
Nirmal Bang Maintains 'Hold' On Mankind Pharma Shares, Revises Target Price — Here's Why
Nirmal Bang maintain Hold rating on Mankind Pharma with a revised target price of Rs 2,650, valuing it at 25x on FY27E EV/Ebitda.
12 Jun 2025, 11:51 AM IST 
Mankind Pharma's Q4 FY25, domestic business (ex-consumer business) revenues increased 9% YoY to Rs 23.6 billion, driven by the acquired BSV portfolio. (Photo source: pxhere)
Mankind Pharma’s strong domestic leadership, increasing focus on Chronic therapies, promising Consumer Healthcare and BSV (Bharat Serums and Vaccines) vaccine portfolio along with compelling margin and return profiles, position it well for sustainable growth.
I’m already a Subscriber
To continue reading this storySubscribe to Unlock & Enjoy your
Subscriber-Only benefits
Subscriber-Only benefits
Choose a plan
Renews automatically. Cancel anytime.
As a Subscriber you get
Access to
Stories
Curated
Newsletters
20,000+
Research Reports
Priority Pass
to Special Events
Ad-Lite
Experience
Subscriber-Only
Rewards
NDTV Profit
Exclusive Stories
Full Access to
NDTV Profit App
Access to
Stories20,000+
Research Reports
Ad-Lite
Experience
NDTV Profit
Exclusive Stories
Curated
Newsletters
Priority Pass
to Special Events
Subscriber-Only
Rewards
Full Access to
NDTV Profit App
Still Not convinced ? Know More
